AG Mednet’s Judi Chosen to Manage 45,000 Adjudication Endpoints and Adverse Events in the Last 24 Months

AG Mednet is making significant progress in providing needed technology for endpoint adjudication in clinical trials, now chosen to manage more than 45,000 adverse events. Judi, the first comprehensive electronic endpoint adjudication system to manage workflow and ensure data quality, is AG Mednet’s solution for sponsors and CROs to manage clinical events from trigger to […]

Read More...

AG Mednet Achieves EU-U.S. Privacy Shield and U.S.-Swiss Privacy Framework Compliance

Taking steps to further enhance medical data protection, AG Mednet is now EU-U.S. Privacy Shield-Certified and U.S.-Swiss Privacy Framework compliant via self-certification. AG Mednet technology is used in clinical trials in more than 80 countries including most European Union nations. The company is committed to the highest levels of data protection available to its customers […]

Read More...

Improve data management to improve endpoint adjudication success in clinical trials

In the winter issue of International Clinical Trials, CEO Abraham Gutman writes about how poor management of data is one of the factors ailing adverse event and endpoint adjudication in clinical trials. The clinical trial industry is transforming, and the vision for this is simple: embrace quality and automation across the clinical trial spectrum and […]

Read More...

Unique Needs for Medical Device Clinical Trials

AG Mednet’s Brian Kelly joins experts from Oracle to address data quality and compliance in medical device trials during this upcoming webcast. The webcast – Adaptive Medical Device Trials for Fast, Seamless and Accurate Research – takes place Thursday, January 25, 2018, noon EST. Medical device studies are complex and unique, with evolving regulatory oversight […]

Read More...

FDA draft guidance and clinical trials

In 2015, the Food and Drug Administration released the Clinical Trial Imaging Endpoint Process Standards draft guidance for the clinical trial industry. According to the FDA, the purpose of the guidance is to assist sponsors in optimizing the quality of imaging data obtained in clinical trials intended to support approval of drugs and biological products. More specifically, […]

Read More...